Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.

Pharmacogenomics - 1 May 2018

Bergmeijer Thomas O, Vos Gerrit Ja, Claassens Daniël Mf, Janssen Paul Wa, Harms Remko, der Heide Richard van, Asselbergs Folkert W, Ten Berg Jurriën M, Deneer Vera Hm

Abstract excerpt

AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to Myocardial Infarction

Share to Percutaneous Coronary Intervention

Share to Pharmacogenomic Testing

Share to Platelet Aggregation Inhibitors

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 29701129
DOI: 10.2217/pgs-2018-0013
PMCID: PMC6021912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.PMID 29701129Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory.Semantic proximity Read ↗

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.Semantic proximity Read ↗

Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy.Semantic proximity Read ↗

Comparison of Two Point-of-Care CYP2C19 Genotyping Assays for Genotype-Guided Antiplatelet Therapy.Semantic proximity Read ↗

Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.Semantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

Point of care CYP2C19 genotyping after percutaneous coronary intervention.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.Semantic proximity Read ↗

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.